The FDA’s Office of Therapeutic Products (OTP) is taking strategic steps to support the gene therapy industry, aiming to approve 10-20 cell and gene therapy (CGT) products annually by 2025. Initiatives like CoGenT and START enhance global collaboration and accelerate rare disease therapeutics development.